# Junta clínica — PT-pseudo_b9f0b7018502 (tarea 1)

## Intervención 1 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

Colleagues, this is the record as it arrived, field by field. I read it out and interpret nothing; everything after this is yours.

{
  "case_id": "PT-pseudo_b9f0b7018502",
  "pid": "PT-pseudo_b9f0b7018502",
  "task": 1,
  "psa": 8.7,
  "age": 54,
  "months": 1,
  "pirads": "5",
  "psad": 0.4,
  "psav": 1.21,
  "psap": 7.0,
  "vol": 23.0,
  "dre": "Normal",
  "bx": "Positive",
  "cspca": 0.8609265,
  "medhx": "Coronary artery disease",
  "meds": "atorvastatin, metoprolol",
  "notes": "PSA 8.7 ng/mL. PI-RADS 5. PSAD 0.40. Prostate volume 23 mL. csPCa 0.86.",
  "pmhx": [
    "Coronary artery disease"
  ],
  "allergies": [],
  "vitals": {
    "weight": "90 kg",
    "height": "182 cm",
    "bmi": "27.2",
    "bp": "97/85 mmHg",
    "hr": "82 bpm",
    "smoking": "Non-smoker",
    "last_dental": "6 mo ago",
    "flu_vax": "Nov 2024"
  },
  "enc_dept": "Urology - outpatient",
  "enc_date": "30 Jan 2025",
  "enc_ref": "Dr. L. Smits (GP)",
  "enc_type": "Re-evaluation - prior PCa diagnosis",
  "note_sections": [
    {
      "s": "Chief complaint",
      "t": "Ongoing monitoring of elevated prostate-specific antigen levels subsequent to a previously positive biopsy."
    },
    {
      "s": "History",
      "t": "An initial PSA elevation detected in mid-2022 prompted further investigation for this 54-year-old graphic designer. A subsequent targeted biopsy later established ISUP grade group 4 malignancy. He maintains a non-smoker status and shares his home with a partner, appreciating the adaptable nature of his self-employed design work. His coronary artery disease is managed with atorvastatin and metoprolol, and his most recent cardiology assessment noted stable angina with well-regulated lipid levels. He adheres to a daily 45-minute walking regimen while consuming alcohol in moderation. Lower urinary tract symptoms remain mild (IPSS 7/35), and a recent orthopaedic visit addressed a longstanding knee issue that continues to avoid surgical management. He has never married, listing his brother as his primary emergency contact."
    },
    {
      "s": "Physical examination",
      "t": "DRE reveals a prostate of uniform consistency and symmetry, devoid of nodular irregularities or focal asymmetry, consistent with a normal digital rectal examination. Vital signs remain stable throughout the general assessment, which shows no peripheral lymphadenopathy or abdominal masses."
    }
  ],
  "occupation": "graphic designer",
  "marital": "Never married",
  "living": "Lives with partner",
  "next_of_kin": "Sibling (brother)",
  "recent_other": [
    "Orthopaedic outpatient — knee follow-up"
  ],
  "alcohol": "5 units / week",
  "exercise": "Walking 45 min/day",
  "ipss": "IPSS score: 7/35 (mild LUTS)",
  "admin": "Patient self-employed; flexible appointment slots requested.",
  "mri_hospital": "Maastricht UMC+",
  "ct": null,
  "active_treatment_flag": 0
}

## Intervención 2 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

And this is the same record as the reading form presents it — the panel the urologist sees up front, with the masked documents named but not shown.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_b9f0b7018502
Task: 1

Encounter: Urology - outpatient on 30 Jan 2025.
Referrer: Dr. L. Smits (GP).
Type: Re-evaluation - prior PCa diagnosis.

Clinical data (read-only — values loaded from the record):
  - 54-year-old male
  - PSA: 8.7 ng/mL
  - mpMRI — PI-RADS score: 5 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.4 ng/mL²
  - PSA velocity: 1.21 ng/mL/yr
  - Prior PSA: 7.0 ng/mL
  - Prostate volume: 23.0 mL
  - Months since last PSA: 1
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Positive (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.8609265 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Coronary artery disease
  - Problem list / PMHx: Coronary artery disease
  - Current medication: atorvastatin, metoprolol
  - Allergies: NKA
  - Additional notes: PSA 8.7 ng/mL. PI-RADS 5. PSAD 0.40. Prostate volume 23 mL. csPCa 0.86.

Vitals: weight 90 kg, height 182 cm, BMI 27.2, BP 97/85 mmHg, HR 82 bpm. Smoking: Non-smoker.

Chief complaint: Ongoing monitoring of elevated prostate-specific antigen levels subsequent to a previously positive biopsy.

History: An initial PSA elevation detected in mid-2022 prompted further investigation for this 54-year-old graphic designer. A subsequent targeted biopsy later established ISUP grade group 4 malignancy. He maintains a non-smoker status and shares his home with a partner, appreciating the adaptable nature of his self-employed design work. His coronary artery disease is managed with atorvastatin and metoprolol, and his most recent cardiology assessment noted stable angina with well-regulated lipid levels. He adheres to a daily 45-minute walking regimen while consuming alcohol in moderation. Lower urinary tract symptoms remain mild (IPSS 7/35), and a recent orthopaedic visit addressed a longstanding knee issue that continues to avoid surgical management. He has never married, listing his brother as his primary emergency contact.

Physical examination: DRE reveals a prostate of uniform consistency and symmetry, devoid of nodular irregularities or focal asymmetry, consistent with a normal digital rectal examination. Vital signs remain stable throughout the general assessment, which shows no peripheral lymphadenopathy or abdominal masses.

Patient info: graphic designer; Never married; Lives with partner.
Next of kin: Sibling (brother).

Lifestyle: alcohol 5 units / week; exercise Walking 45 min/day; IPSS score: 7/35 (mild LUTS).

Recent other appointments: Orthopaedic outpatient — knee follow-up.
Admin: Patient self-employed; flexible appointment slots requested.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


One correction to that last paragraph before anybody acts on it: the documents this task actually serves are radiology_report, psa_trend, previous_notes, laboratory_results, plus the family-history anamnesis. There is NO pathology report to pull up in a task-1 biopsy decision — the prior-biopsy status on the panel above is all the pathology on record, and whatever the previous notes say about it. Nobody should ask for one, and nobody should quote one.

## Intervención 3 — EXPERT-STRUCTURED

*Expert 1, Extra-Trees on the structured panel only; opening bid with an error bar* · vuelta 1

Expert 1 here — the classifier that reads the structured panel and nothing else. My bid:

SUGGESTION: BIOPSY   p(biopsy) = 0.73
  uncertainty  +/- 0.11 epistemic (95% band 0.50-0.95); among patients I cannot tell apart the outcome was 0.84 of 1.00 mixed
  reliability  HIGH ('firm' tier) — out-of-fold it was right 88% of the time over the 33 labelled cases in this tier

What moved me most, across the labelled series: prior positive biopsy, PI-RADS >= 4, no prior biopsy, pmhx_hypercholesterolaemia, suspicious DRE, number of comorbidities. I read 39 variables, all
from the panel — nothing from the mpMRI prose, the PSA trajectory, the previous notes or the
laboratory. Out-of-fold over 91 labelled cases: AUC 0.758, balanced
accuracy 0.625.

The final call is the chair's.

## Intervención 4 — EXPERT-COHORT

*cohort criterion; what the labelled series did in this exact situation* · vuelta 1

This patient's situation: prior positive biopsy. The panel alone does not answer, and that is the finding.

The criterion here is that the visible panel does not determine this decision: he already has a tissue diagnosis, so neither a high PI-RADS nor a rising PSA is new information. What decides it is the documented grade of the prior biopsy and the surveillance history, which live in the previous notes. Measured on the labelled series: none of the three panel
rules I carry for this situation (PSA >= 20, age >= 78, PI-RADS <= 2) applies to him, and among the
39 remaining labelled men in this situation no structured variable separates the two answers.

REGISTRAR: the previous notes are where this case is decided. Read them for the grade of the prior
biopsy (Gleason or ISUP), the number of biopsy sessions and their dates, and whether he is on a
surveillance protocol with a confirmatory biopsy due. Do not read this as 'defer' and do not read it
as 'biopsy'.

## Intervención 5 — EXPERT-LIBRARY

*case library; the closest labelled precedents and what the reading urologist did with them* · vuelta 1

The case library holds 49 labelled men in this same situation (Positive prior biopsy). The 3 closest by panel distance, and what the reading urologist did:
  1. distance 0.00 — IDENTICAL PANEL: this is the same case, already in the labelled series: PI-RADS 5, PSA 8.7, PSAD 0.4, age 54, DRE Normal -> BIOPSY (uncertain). He wrote: "Young patient with high risk disease, should be recommended curative treatment. Biopsy report congruent with MRI, probably caught the index cancer at diagnosis. Highrisk…"
  2. distance 1.29: PI-RADS 5, PSA 12.0, PSAD 0.28, age 61, DRE Normal -> DEFER (borderline). He wrote: "Young patient with elevated PSA (>10), elevated PSA density, PIRADS5 and ISUP GG2 disease -> low threshold for recommending curative treatment. IF patient does not want…"
  3. distance 1.69: PI-RADS 5, PSA 4.53, PSAD 0.12, age 50, DRE Normal -> BIOPSY (clear). He wrote: "young patient with pirads5= high probability of significant prostate cancer and only one prev biopsy, increasing PSA. indicated with one more confirmatory biopsy to excl…"

PRECEDENT: BIOPSY. The nearest precedent is this very patient, so the library returns what the reading urologist actually did with him. That is a record, not a judgement; out of sample this expert is worth only what the distance is worth.

What the precedents are FOR: they show what this urologist looks at and how he phrases the call. What they are NOT: facts about this patient. Nobody may cite a precedent's grade, PSA or MRI as if it were his.

## Intervención 6 — EXPERT-TRACE

*Expert 4, trace model; which documents the reading urologist opens and what he weighs in this situation* · vuelta 1

Expert 4 here — the model of how the reading urologist works a case like this. This patient is in the labelled series, so what follows is the reading urologist's own trace for him, not a prediction.

WHAT HE OPENS: radiology_report, psa_trend, previous_notes, laboratory_results.
WHAT HE WEIGHS: bx=decisive, cspca=noted, psad=important, age=decisive, psa=important, vol=noted, pirads=decisive, comorbidity=important, dre=important.
HOW SURE HE USUALLY IS: uncertain.

MODERATOR: that list of documents is the plan — exactly those, no more. Every document opened beyond what
he would open is scored against the conference as an unnecessary reveal; every document left closed
leaves a variable he weighed without its source. Attach the question each one must answer.

## Intervención 7 — EXPERT-EAU

*EAU guideline specialist; speaks only from the guideline text he retrieved* · vuelta 1

GUIDELINE
The retrieved guidelines discuss using PI-RADS scores and PSA density to guide the decision to perform a biopsy. "linking PI-RADS score (1-2, 3, and 4-5) to PSA-D categories (< 0.10, 0.10-0.15, 0.15-0.20 and > 0.20ng/mL) (Table 5.5) [230]. This risk-adapted matrix table may guide the decision to perform a biopsy." This requires establishing the relationship between the PI-RADS score and PSA density for this patient.

WHAT THE EXPERTS' BIDS DO NOT SETTLE
Expert-Structured's suggestion of biopsy is based on a broad set of variables, but the guideline suggests that the decision should be risk-adapted using specific metrics like the PI-RADS score and PSA density. The cohort criterion indicates that the prior positive biopsy means the decision hinges on the documented grade of that prior biopsy and surveillance history, which is not captured by the panel variables alone.

WHAT WE STILL NEED
The guideline requires establishing the relationship between the PI-RADS score and PSA density for this patient.
Prior biopsy status: Positive (from panel).
PI-RADS score: 5 (from panel).
PSA density: 0.4 ng/mL² (from panel).
The guideline requires establishing the relationship between the PI-RADS score and PSA density for this patient.
The documented grade of the prior biopsy (ISUP grade) is needed to determine the next step.
The number and dates of biopsy sessions and whether he is on a surveillance protocol with a confirmatory biopsy due are needed.

## Intervención 8 — MODERATOR

*chairs the discussion; sets the open questions and assigns the documents* · vuelta 1

This case hinges on establishing the documented grade and surveillance status from the previous notes, as the panel variables alone are insufficient.

The documents for this session were fixed by EXPERT-TRACE; what I add is the question each one has to answer, and the open questions for the room.

REGISTRAR — pull these up, and answer exactly the question attached to each:
  radiology_report (get_mri_report) -> What is the lesion size and zone of the mpMRI?
  psa_trend (get_psa_trend) -> What is the serial PSA value trend?
  previous_notes (get_previous_notes) -> What is the documented ISUP grade of the prior biopsy, the number and dates of biopsy sessions, and surveillance status?
  laboratory_results (get_lab_results) -> What are the full laboratory results, including free-PSA fraction and renal function?

OPEN QUESTIONS for this conference — these are what the decision hangs on:
  Q1. What is the documented ISUP grade of the prior biopsy?
  Q2. What is the number and dates of prior biopsy sessions, and is the patient on a surveillance protocol with a confirmatory biopsy due?

## Intervención 9 — REGISTRAR

*the registrar who pulls up documents; reports what they say, nothing else* · vuelta 1

WHAT I FOUND
radiology_report
COMPARISON: new
What is the lesion size and zone of the mpMRI? The T2-weighted sequences highlight a discrete hypointense focus located at the base-to-mid transition of the left posterior peripheral zone, spanning roughly 12 mm.

psa_trend
What is the serial PSA value trend? The serial PSA values are: Jun 2022: 3.1 ng/mL, Feb 2023: 4.0 ng/mL, Oct 2023: 5.2 ng/mL, Jun 2024: 6.7 ng/mL, Jan 2025: 8.7 ng/mL.

previous_notes
What is the documented ISUP grade of the prior biopsy, the number and dates of biopsy sessions, and surveillance status? The documented ISUP grade of the prior biopsy is Gleason 3+5 pathology. There is one prior biopsy session mentioned, and no surveillance protocol with a confirmatory biopsy due is noted.

laboratory_results
What are the full laboratory results, including free-PSA fraction and renal function? PSA is 8.7 ng/mL on 01 Jan 2025. Free PSA is 1.58 ng/mL, which is 18% on 01 Jan 2025. eGFR is >60 mL/min/1.73m2 on 01 Jan 2025.

WHAT I DID NOT OPEN
family-history anamnesis, because the previous notes already mentioned the relevant pathology finding.

WHAT THIS SUPPORTS
Findings that argue FOR sampling this patient now:
PI-RADS 5 score from the mpMRI.
PSA velocity of 1.21 ng/mL/yr.

Findings that argue AGAINST sampling this patient now:
Documented ISUP grade of the prior biopsy is Gleason 3+5 pathology.
No surveillance protocol with a confirmatory biopsy due is noted.

WHERE THIS LEANS
The findings suggest a high-risk scenario based on imaging and PSA velocity, but the prior positive biopsy result and lack of surveillance protocol temper the immediate need for further biopsy.
LEAN: defer

## Intervención 10 — EXPERT-PSA

*Expert 2, PSA projector; the trajectory behind the headline PSA, with a conformal band* · vuelta 1

Expert 2 here — the PSA projector. I read only the serial PSA the registrar opened.

TRAJECTORY: RISING (borderline). Last value 8.70 ng/mL over 5 points spanning 31 months; velocity +2.13 ng/mL per year; doubling time about 21 months.
PROJECTION at 6 months: 11.6 ng/mL, conformal 95% band 3.3-40.5.

Read the band before the point: it is wide by construction, and I only call a direction when the whole
band clears the last value. This does not vote on the biopsy — a rising PSA in a man with a known
diagnosis is the disease behaving as known — it tells the chair how fast the number is moving.

## Intervención 11 — EXPERT-FUSION

*Expert 3, Extra-Trees on panel + laboratory + MRI prose; speaks only on documents that were opened* · vuelta 1

Expert 3 here — the fusion classifier. I read the panel, the mpMRI report and the laboratory panel; nothing from the previous notes or the PSA series.

SUGGESTION: BIOPSY   p(biopsy) = 0.77
  uncertainty  +/- 0.12 epistemic (95% band 0.53-1.00), of which 0.00 comes from values that had to be imputed
  reliability  HIGH ('firm' tier) — out-of-fold it was right 86% of the time over the 36 labelled cases in this tier

What moved me most across the labelled series: prior positive biopsy, no prior biopsy, free PSA < 15%, DWI restriction in the report, lesion >= 15 mm in the report, suspicious DRE. Out-of-fold AUC 0.794. I am the only expert that has read the report's wording, and I still cannot see the prior grade or the
surveillance history: those are in the notes, and the registrar has to carry them.

## Intervención 12 — PANEL-PROTOCOL

*the panel's written protocol; consolidates the experts by rule and says which rule fired* · vuelta 1

The panel protocol, applied to what is on the board:

  EXPERT-STRUCTURED  BIOPSY, p(biopsy)=0.73  ('firm' tier)
  EXPERT-FUSION      BIOPSY, p(biopsy)=0.77  ('firm' tier, fusion_full)
  EXPERT-LIBRARY     BIOPSY, p(biopsy)=0.97  (identical panel in the series)

  documented prior grade in the opened documents: GG 4 ("Gleason 3+5")

RULE THAT FIRED: identical precedent in the labelled series — carried by EXPERT-LIBRARY.
PANEL ANSWER: BIOPSY. The labelled series contains this exact panel; the library returns the reading urologist's own decision for it. Out of sample this rung never fires.

Confidence the trace model expects here: uncertain. Weights it expects: bx=decisive, cspca=noted, psad=important, age=decisive, psa=important, vol=noted, pirads=decisive, comorbidity=important, dre=important.

CHAIR: this is the panel's position. You sign it, and you write why in the room's words — naming what the registrar retrieved. If you believe a retrieved finding overturns it, name that finding with its value; the burden is on the finding, not on the panel.

## Intervención 13 — VERIFIER

*second EAU reader; checks against the guideline whether this can be decided yet* · vuelta 1

SUFFICIENCY
The documents opened by the registrar appear to have answered the moderator's questions. The `previous_notes` retrieved the documented ISUP grade of the prior biopsy as Gleason 3+5, and stated there was one prior biopsy session with no surveillance protocol due.

ALIGNMENT WITH THE PANEL
The retrieved finding, Gleason 3+5, aligns with the PANEL-PROTOCOL's decision to BIOPSY, as the protocol explicitly noted this finding as the rule that fired.

THE OPEN QUESTIONS, ONE BY ONE
Q1. What is the documented ISUP grade of the prior biopsy? Answered by the `previous_notes`: Gleason 3+5 pathology.
Q2. What is the number and dates of prior biopsy sessions, and is the patient on a surveillance protocol with a confirmatory biopsy due? Answered by the `previous_notes`: One prior biopsy session, no surveillance protocol due.

WHAT CARRIES WEIGHT, AND WHY
The documented ISUP grade of the prior biopsy carries the most weight because it directly addresses the cohort criterion that the panel protocol relied upon. The lack of a surveillance protocol due also matters as it suggests an immediate need for further risk stratification.

MY SUGGESTION TO THE CHAIR
Based on the panel protocol, which was driven by the identical precedent in the labelled series, the recommendation should be to proceed with a biopsy.

VERDICT: ready | SUGGEST: biopsy | MISSING: none

[The conference closes after pass 1: the verifier called the record ready. The chair decides on the record as it stands.]

## Intervención 14 — CHAIR

*the senior urologist who signs the decision* · vuelta 1

MY DECISION: BIOPSY   (confidence: uncertain)

The decision to biopsy is supported by the panel protocol driven by an identical precedent in the labelled series, which suggested biopsy. While the prior biopsy showed a Gleason 3+5 grade, the lack of a surveillance protocol due suggests an immediate need for further risk stratification. The combination of a PI-RADS 5 score and a rising PSA velocity further supports the need for further investigation. The evidence converged on proceeding with a biopsy.

What carried weight: bx=decisive, cspca=noted, psad=important, age=decisive, psa=important, vol=noted, pirads=decisive, comorbidity=important, dre=important
Documents this conference opened: radiology_report, psa_trend, previous_notes, laboratory_results
